Dyskinesia

Preclinical Aspects.- Brain Dopamine Receptors in Schizophrenia and Tardive Dyskinesia.- Receptor-Binding Profiles of Neuroleptics.- Functional Classification of Different Dopamine Receptors.- Pharmacological Properties of Presynaptic Dopamine Receptor Agonists.- Influence of GABA Mimetics and Lithium on Biochemical Manifestations of Striatal Dopamine Target Cell Hypersensitivity.- New Aspects on the Role of Dopamine, Acetylcholine, and GABA in the Development of Tardive Dyskinesia.- Discussion Section.- Differential Effects of Dopamine D-1 and D-2 Agonists and Antagonists in 6-Hydroxydopamine-Lesioned Rats.- Clinical Aspects.- Is Tardive Dyskinesia a Unique Disorder?.- Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors.- Involuntary Disorders of Movement in Chronic Schizophrenia - The Role of the Illness and Its Treatment.- Tardive Dyskinesia: Reversible and Irreversible.- Pathophysiological Mechanisms Underlying Tardive Dyskinesia.- Chemical and Structural Changes in the Brain in Patients with Movement Disorder.- Medical Treatment of Dystonia.- The Effect of Dopamine Antagonists in Spontaneous and Tardive Dyskinesia.- GABA Dysfunction in the Pathophysiology of Tardive Dyskinesia.- Clinical Activity of GABA Agonists in Neuroleptic- and L-Dopa-Induced Dyskinesia.- Tardive Dyskinesia: Nondopaminergic Treatment Approaches.- Pathophysiology of L-Dopa-Induced Abnormal Involuntary Movements.- Discussion Section.- Prevalence of Tardive Dyskinesia in a Clinic Population.- Animal Models.- Differential Alteration of Striatal D-1 and D-2 Receptors Induced by the Long-Term Administration of Haloperidol, Sulpiride or Clozapine to Rats.- Pharmacological Differentiation of Dopamine D-1 and D-2 Antagonists After Single and Repeated Administration.- Pathophysiology ofTardive Dyskinesia.- Intermittent Treatment with Droperidol, a Short-Acting Neuroleptic, Increases Behavioral Dopamine Receptor Sensitivity.- Induction and Reversal of Dopamine Dyskinesia in Rat, Cat, and